Brokerages Set Sutro Biopharma, Inc. (NASDAQ:STRO) PT at $4.47

Key Points

• Sutro Biopharma, Inc. (NASDAQ:STRO) has received an average rating of "Hold" from analysts, with one sell recommendation, four holds, and two buys.
• Currently, Sutro Biopharma's shares are trading at about $0.86, significantly below their 52-week high of $4.80.
• In its latest earnings report, Sutro Biopharma reported a revenue of $63.74 million, exceeding the consensus estimate of $14.55 million, despite a negative net margin of 201.32%.

Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has been assigned a consensus recommendation of "Hold" from the seven research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $4.4667.

Several research analysts have weighed in on STRO shares. Wall Street Zen lowered Sutro Biopharma from a "hold" rating to a "sell" rating in a research report on Friday, August 22nd. Bank of America lowered their price target on Sutro Biopharma from $1.00 to $0.80 and set an "underperform" rating on the stock in a research report on Monday, May 19th. Wells Fargo & Company lowered their price target on Sutro Biopharma from $4.00 to $3.00 and set an "equal weight" rating on the stock in a research report on Tuesday, August 12th. Finally, Piper Sandler raised Sutro Biopharma from a "neutral" rating to an "overweight" rating and set a $2.00 price target on the stock in a research report on Monday, June 16th.

Sutro Biopharma Stock Performance

NASDAQ STRO traded up $0.01 during trading on Friday, hitting $1.02. The stock had a trading volume of 535,332 shares, compared to its average volume of 447,711. The company has a market capitalization of $86.47 million, a PE ratio of -0.40 and a beta of 1.57. The company's 50-day moving average price is $0.82 and its two-hundred day moving average price is $0.91. Sutro Biopharma has a 12 month low of $0.52 and a 12 month high of $4.80.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.25. The firm had revenue of $63.74 million for the quarter, compared to analysts' expectations of $14.55 million. Sutro Biopharma had a negative return on equity of 852.70% and a negative net margin of 201.32%. As a group, equities analysts anticipate that Sutro Biopharma will post -2.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Suvretta Capital Management LLC increased its holdings in shares of Sutro Biopharma by 3.8% during the 4th quarter. Suvretta Capital Management LLC now owns 7,462,495 shares of the company's stock worth $13,731,000 after acquiring an additional 275,000 shares during the last quarter. RA Capital Management L.P. acquired a new position in shares of Sutro Biopharma during the 1st quarter worth approximately $2,885,000. Acadian Asset Management LLC increased its holdings in shares of Sutro Biopharma by 78.9% during the 1st quarter. Acadian Asset Management LLC now owns 3,134,586 shares of the company's stock worth $2,037,000 after acquiring an additional 1,382,661 shares during the last quarter. Velan Capital Investment Management LP increased its holdings in shares of Sutro Biopharma by 197.1% during the 2nd quarter. Velan Capital Investment Management LP now owns 3,060,000 shares of the company's stock worth $2,185,000 after acquiring an additional 2,030,000 shares during the last quarter. Finally, Vestal Point Capital LP increased its holdings in shares of Sutro Biopharma by 1.2% during the 1st quarter. Vestal Point Capital LP now owns 2,600,000 shares of the company's stock worth $1,692,000 after acquiring an additional 30,000 shares during the last quarter. 96.99% of the stock is owned by institutional investors and hedge funds.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.